Shuting Li
Impact in
- Oncology top 10%
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Rehabilitation top 5%
- Wound Healing and Treatments
Papers in
- Epidemiology 12
- Co-authors
- Jinwan Wang (3 shared papers)Yihebali Chi (2 shared papers)Wei Niu (2 shared papers)Li Li (2 shared papers)Chuan Li (2 shared papers)Yongkun Sun (2 shared papers)Chunxia Du (2 shared papers)Hao Yu (1 shared paper)
- Journals
- Frontiers in Public Health (3 papers)Journal of Global Health (3 papers)Frontiers in Endocrinology (3 papers)Journal of Agricultural and Food Chemistry (2 papers)International Journal of Biological Macromolecules (2 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Shuting Li
91 papers receiving 1.5k citations
Shuting Li's Hit Papers
Peers
Comparison fields: 5 of 145
- Oncology 410
- Rehabilitation 82
- Pulmonary and Respiratory Medicine 298
- Endocrinology, Diabetes and Metabolism 149
- Nephrology 61
Countries citing papers authored by Shuting Li
This map shows the geographic impact of Shuting Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuting Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuting Li more than expected).
Fields of papers citing papers by Shuting Li
This network shows the impact of papers produced by Shuting Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuting Li. The network helps show where Shuting Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Shuting Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 101 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors Hit paper breakdown → | 2016 | 332 |
| 2 | 2017 | 77 | |
| 3 | 2017 | 44 | |
| 4 | 2021 | 42 | |
| 5 | 2019 | 41 | |
| 6 | 2019 | 41 | |
| 7 | 2022 | 40 | |
| 8 | 2024 | 37 | |
| 9 | 2023 | 37 | |
| 10 | 2021 | 37 | |
| 11 | 2020 | 36 | |
| 12 | 2022 | 36 | |
| 13 | 2022 | 32 | |
| 14 | 2022 | 31 | |
| 15 | 2022 | 30 | |
| 16 | 2016 | 29 | |
| 17 | 2017 | 26 | |
| 18 | 2020 | 26 | |
| 19 | 2017 | 24 | |
| 20 | 2022 | 24 |
About Shuting Li
Shuting Li is a scholar working on Molecular Biology, Epidemiology, Pulmonary and Respiratory Medicine, Health, Toxicology and Mutagenesis and Oncology, having authored 101 papers that have together received 1.6k indexed citations. Recurring topics across this work include Wound Healing and Treatments (8 papers), Air Quality and Health Impacts (6 papers), Retinal Diseases and Treatments (5 papers), Blood Pressure and Hypertension Studies (5 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (5 papers), Genetic factors in colorectal cancer (4 papers), Birth, Development, and Health (4 papers) and Obesity, Physical Activity, Diet (4 papers). The work is most often cited by research in Oncology (410 citations), Rehabilitation (82 citations), Pulmonary and Respiratory Medicine (298 citations), Endocrinology, Diabetes and Metabolism (149 citations) and Nephrology (61 citations). Shuting Li has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Jinwan Wang, Yihebali Chi, Wei Niu, Li Li, Chuan Li, Yongkun Sun, Chunxia Du, Hao Yu, Feng‐Qing Wang and Feng Du. Their work appears in journals such as Frontiers in Public Health, Journal of Global Health, Frontiers in Endocrinology, Journal of Agricultural and Food Chemistry and International Journal of Biological Macromolecules.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.